Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS

被引:1
|
作者
Jin, Xiu [1 ]
Liu, Feifei [1 ]
Zhang, Ya [2 ]
Ma, Yingying [3 ]
Yang, Linqing [3 ]
Wang, Yunfei [3 ]
Liu, Ying [3 ]
机构
[1] Jining Med Univ, Affiliated Hosp, Dept Pathol, Jining, Shandong, Peoples R China
[2] Jining Med Univ, Affiliated Hosp, Dept Obstet, Jining, Shandong, Peoples R China
[3] Jining Med Univ, Dept Gynecol, Affiliated Hosp, Jining, Shandong, Peoples R China
关键词
Cervical cancer; ASCUS; HPV E6/E7 mRNA; Menopause; Colposcope; CERVICAL-CANCER; PREVENTION; WOMEN; PERFORMANCE; POPULATION; LESIONS;
D O I
10.1186/s12905-023-02599-3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To investigate the infection status of high-risk human papillomavirus (HR-HPV) E6/E7 mRNA in patients with a cytological diagnosis of "atypical squamous cells of undetermined significance" (ASCUS) and to analyze the pathogenic rate of different high-risk HPV subtypes combined with biopsy pathological results to provide a more accurate basis for managing ASCUS patients.Methods A total of 1387 patients with ASCUS and HPV E6/E7 mRNA positivity who were referred for colposcopy were retrospectively analyzed. They were divided into HPV16+, 18/45 + and other HR-HPV + groups premenopausal and postmenopausal groups. The pathological results of the biopsy were divided into the LSIL- group (including normal and low-grade squamous intraepithelial lesions) and the HSIL + group (including high-grade squamous intraepithelial lesions and higher lesions). SPSS was used for the analysis.Results The age group 31-40 years had the highest level of HPV16+, and HPV18/45 + was the highest in the 41-50 years group. The detection rates of HSIL + in the HPV16+, HPV18/45+, HPV 16/18/45 + and Other HR-HPV + groups were 48.4%, 18.8%, 43.9% and 15.0%, respectively. The infection rates of HPV16/18/45 in postmenopausal and premenopausal women were 42.4% and 34.3%, respectively. In the HPV18/45 group, the incidence of HSIL + was 30.0% in postmenopausal women and 15.0% in premenopausal women (P < 0.01). In the HPV 16 + and Other HR-HPV + groups, the incidence of HSIL + in postmenopausal patients was not significantly different from that in premenopausal patients. The incidence of cervical cancer in postmenopausal patients is significantly higher than that in premenopausal patients.Conclusions Colposcopy referral or further biopsy is recommended for all ASCUS patients with HPV16/18/45E6/E7 mRNA positivity and postmenopausal patients with HR-HPVE6/E7 mRNA positivity. For premenopausal ASCUS patients with other HR-HPV E6/E7 mRNA positivity, colposcopy should be performed if possible, depending on the specific situation, to achieve early detection and diagnosis.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Diagnostic value of high-risk HPV E6/E7 mRNA in patients with ASCUS
    Xiu Jin
    Feifei Liu
    Ya Zhang
    Yingying Ma
    Linqing Yang
    Yunfei Wang
    Ying Liu
    BMC Women's Health, 23
  • [2] E6/E7 mRNA Expression of High-risk HPV Types in 849 Greek Women
    Argyri, Elena
    Tsimplaki, Elpida
    Daskalopoulou, Dimitra
    Stravopodis, Dimitrios J.
    Kouikoglou, Ourania
    Terzakis, Emmanouil
    Panotopoulou, Efstathia
    ANTICANCER RESEARCH, 2013, 33 (09) : 4007 - 4011
  • [3] THE CARCINOGENIC POTENTIAL OF E6 & E7 GENES OF HIGH-RISK HPV COMPARED WITH E6, E7 GENES OF LOW-RISK HPV IN HUMAN CERVICAL CANCER: A REVIEW
    Gill, Sher Singh
    Jana, A. M.
    Shrivastav, Archana
    Sharma, Sachin
    Sharma, Arvind
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2014, 5 (03): : 703 - 712
  • [4] The clinical value of HPV E6/E7 and STAT3 mRNA detection in cervical cancer screening
    Fan, Yibing
    Shen, Zongji
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (05) : 767 - 775
  • [5] The Potential Benefits of HPV E6/E7 mRNA Test in Cervical Cancer Screening in China
    Zhang, Shao-Kai
    Guo, Zhen
    Wang, Peng
    Kang, Le-Ni
    Jia, Man-Man
    Wu, Ze-Ni
    Chen, Qiong
    Cao, Xiao-Qin
    Zhao, Dong-Mei
    Guo, Pei-Pei
    Sun, Xi-Bin
    Zhang, Jian-Gong
    Qiao, You-Lin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Do women with high-risk HPV E6/E7 mRNA test positivity and NILM cytology need colposcopy?
    Ying Liu
    Xiu Jin
    Yingying Gong
    Yingying Ma
    Beibei Du
    Linqing Yang
    Yunfei Wang
    Weipei Zhu
    Infectious Agents and Cancer, 18
  • [7] The Expression of HPV E6/E7 mRNA In Situ Hybridization in HPV Typing-negative Cervical Cancer
    Xu, Yating
    Sun, Yonghong
    Chang, Hui
    Cai, Jingjing
    Cao, Chengcheng
    Zhang, Baogang
    Zhang, Youzhong
    Liu, Yuzhen
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2023, 42 (01) : 11 - 20
  • [8] High-Risk Human Papillomavirus Oncogenic E6/E7 mRNAs Splicing Regulation
    Zheng, Yunji
    Li, Xue
    Jiao, Yisheng
    Wu, Chengjun
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [9] The presence of high-risk human papillomavirus (HPV) E6/E7 mRNA transcripts in a subset of sinonasal carcinomas is evidence of involvement of HPV in its etiopathogenesis
    Laco, Jan
    Sieglova, Katerina
    Vosmikova, Hana
    Dundr, Pavel
    Nemejcova, Kristyna
    Michalek, Jaroslav
    Celakovsky, Petr
    Chrobok, Viktor
    Mottl, Radovan
    Mottlova, Alena
    Tucek, Lubo
    Slezak, Radovan
    Chmelarova, Marcela
    Sirak, Igor
    Vosmik, Milan
    Ryska, Ales
    VIRCHOWS ARCHIV, 2015, 467 (04) : 405 - 415
  • [10] Treatment of first-void urine with Aptima Transfer Solution increases detection of high-risk HPV E6/E7 mRNA
    Arias, Manuel
    Jang, Dan
    Dockter, Janel
    Ratnam, Sam
    Shah, Anika
    Elit, Laurie
    Smieja, Marek
    Lytwyn, Alice
    Getman, Damon
    Weinbaum, Barbara
    Chernesky, Max
    JOURNAL OF VIROLOGICAL METHODS, 2019, 267 : 48 - 52